Company / Cash & Equivalents
AGIOS PHARMACEUTICALS, INC. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$89.1M
FY2025
5-year range
$76.2M / $203.1M
FY2021-FY2025
Trend
+16.9%
vs FY2024
Sector context
#149 of 207
Health Care
What the data says
At $89M, AGIOS PHARMACEUTICALS, INC.'s cash & equivalents ranks #149 of 207 in the Health Care sector. Cash & Equivalents returned to growth in FY2025 after 3 years of decline, reaching $89M.
Based on SEC 10-K filings.
$89M in FY2025 with a 5-year CAGR of -6.9%.
Remained stable around $89M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -13.8%
- 5-Year CAGR
- -6.9%
- 10-Year CAGR
- -
Sector benchmark
#149 of 207 in Health CareTop 72% of 207This company $89.1M Sector average $669.5M
▼
-86.7% below sector average
Key checks
Key Insights
- 5-year CAGR of -6.9%, indicating a declining trend.
- In FY2025, cash & equivalents increased 16.9% year-over-year.
- Ranks #149 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.83 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $89.1M | +16.9% |
| FY2024 | $76.2M | -13.6% |
| FY2023 | $88.2M | -36.7% |
| FY2022 | $139.3M | -31.4% |
| FY2021 | $203.1M | +59.4% |
| FY2020 | $127.4M | +57.5% |
| FY2019 | $80.9M | +14.8% |
| FY2018 | $70.5M | -31.4% |
| FY2017 | $102.7M | -36.1% |
| FY2016 | $160.8M | +124.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026